این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Medical Sciences، جلد ۵۱، شماره ۳، صفحات ۱۸۶-۱۹۵
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The Association between Serum Biochemical Markers and Early Amniocentesis in Diagnosing Chromosomal Anomalies: A Cross-Sectional Study in Southern Iran, 2021-2022
چکیده انگلیسی مقاله Background: Efforts to improve prenatal diagnosis of Down syndrome have been made, with amniocentesis representing an invasive procedure, and maternal serum biochemical markers are among the non-invasive options. This study aimed to examine the association between serum biochemical marker values and amniocentesis results in the prenatal diagnostics of Down syndrome in early pregnancy.
Methods: In a cross-sectional study, data from pregnant women in the first trimester undergoing amniocentesis test for the diagnosis of fetal genetic diseases were collected during 2021-2022. Maternal weight, maternal age, gestational age at nuchal translucency (NT) scan, nasal bone (NB) status, and serum chemical biomarkers—including pregnancy-associated plasma protein-A (PAPP-A), and beta-human chorionic gonadotropins (β-hCG) were assessed. 
Results: Of 1,987 amniocentesis cases, 96.5% were normal, and 3.5% were abnormal. Down syndrome was present in approximately 3% of cases. Maternal weight was significantly lower in the abnormal amniocentesis group than in the normal group. After adjusting for maternal weight, maternal age, NT, and β-hCG were significantly higher in the abnormal amniocentesis group, whereas PAPP-A was lower. The NB status did not differ between groups. A PAPP-A level of <0.42 multiple of median (MoM) (sensitivity=90%, specificity=68%) and a β-hCG level of ≥1.52 MoM (sensitivity=76%, specificity=70%) acceptably predicted Down syndrome in abnormal amniocentesis cases. Among the 69 abnormal amniocentesis cases, 49 cases had Down syndrome; of these, 75.5% had a Down syndrome risk of ≤1:100.
Conclusion: Both β-hCG and PAPP-A had independent diagnostic value in predicting Down syndrome in early pregnancy. It is recommended that a Down syndrome risk of up to 1:100 warrant direct amniocentesis, while cases with a risk greater than 1:100 should be offered non-invasive alternatives.
کلیدواژه‌های انگلیسی مقاله Maternal serum screening tests,Chromosome disorders,Amniocentesis
نویسندگان مقاله Maryam Kasraeian |
Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Mehdi Dianatpour |
Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Marzie Zare |
Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Marjan Zare |
Department of Public Health, Khalkhal University of Medical Sciences, Khalkhal, Iran

Azam Faraji |
Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Homeira Vafaei |
Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Nasrin Asadi |
Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Khadije Bazrafshan |
Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

نشانی اینترنتی https://ijms.sums.ac.ir/article_51597_f008649c21ed8330253fa79463024c9a.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات